<DOC>
	<DOC>NCT02717611</DOC>
	<brief_summary>A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy</brief_summary>
	<brief_title>A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>1. Men and women ≥ 18 years of age. 2. Prior diagnosis of CLL 3. Must have received ≥ 1 prior therapy for CLL 4. Intolerant of ibrutinib 5. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty. 6. ECOG performance status of ≤ 2. 1. Ongoing AE attributed to ibrutinib therapy 2. Treatment with systemic anticancer therapy for CLL is prohibited between discontinuation of ibrutinib and enrollment on this trial. 3. Prior exposure to a BCL2 inhibitor (eg, venetoclax/ABT199) 4. Prior malignancy (other than CLL), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the subject has been disease free for ≥ 2 years. 5. Significant cardiovascular disease such as uncontrolled or symptomatic untreated arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc &gt; 480 msec at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ibrutinib Intolerant</keyword>
</DOC>